

# 温度对志贺氏菌毒力的影响

---

---




王恒桀


病原微生物生物安全国家重点实验室  
军事医学科学院生物工程研究所



# 学科研究方向——病原细菌的防控研究




# 微生物蛋白质组学技术在病原菌防控中的应用



# 研究志贺氏菌的重要性(一) (志贺氏菌俗称痢疾杆菌)


## ● 高发病率(极低的感染剂量)

Test strain	Reference	Administered dose*	No. volunteers	No. ill (%)†
<i>S. flexneri</i> 2a, 2457T	3-5	100	36	14 (39)
		180	36	9 (25)
		$5 \times 10^3$	49	28 (57)
		$10^4$	103	58 (56)
		$10^5-10^8$	59	38 (64)
<i>S. dysenteriae</i> 1	A-1	200	8	3 (38)
		$10^4$	6	2 (33)
	M-131	10	10	1 (10)
		200	4	2 (50)
		$2 \times 10^3$	10	7 (70)
		$10^4$	6	5 (83)
<i>S. sonnei</i>	none	500	20	7 (35)
		500	38	19 (50)



# 研究志贺氏菌的重要性(二)

- 对儿童危害巨大



ELSEVIER

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SCIENCE @ DIRECT®

Vaccine 24 (2006) 2732–2750

Vaccine

[www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

Review

A review of vaccine research and development: human enteric infections<sup>☆</sup>

Marc P. Girard<sup>a,\*</sup>, Duncan Steele<sup>b,1</sup>, Claire-Lise Chaignat<sup>c,1</sup>, Marie Paule Kieny<sup>b,\*,1</sup>

<sup>a</sup> University Paris 7, UFR Biochemistry, 39 rue Seignemartin, 69008 Lyon, France

<sup>b</sup> Initiative for Vaccine Research, World Health Organization, 20 Avenue Appia, CH 1211-Geneva, Switzerland

<sup>c</sup> Communicable Disease Cluster, World Health Organization, 20 Avenue Appia, CH 1211-Geneva, Switzerland

# 研究志贺氏菌的重要性(三)


- 高耐药性

- 缺乏理想的疫苗

- 在生物安全方面的潜在危害 (Category B)


Antimicrobial agent <sup>a</sup>	% of strains <sup>b</sup>		
	R	I	S
Ampicillin	100	0	0
Amoxicillin-clavulanic acid	0	0	100
Ampicillin-sulbactam	2.6	68.1	24.1
Ticarcillin-clavulanic acid	0	0.9	99
Piperacillin-tazobactam	0	0	100
Piperacillin	12.9	5.2	73.3
Aztreonam	38.8	2.6	58.6
Cefepime	34.5	0.9	95.7
Cefotaxime	6.1	0.9	93.1
Ceftazidime	0	0.9	99
Ceftriaxone	5.2	0	94.8
Ciprofloxacin	13.8	0.9	85.3
Gatifloxacin	0	0.9	99
Levofloxacin	0.9	10.3	88.8
Imipenem	0	0	100
Trimethoprim-sulfamethoxazole	89.7	0	10.3
Nalidixic acid	100		0
Chloramphenicol	96.20		0.8
Tetracycline	99.06		0.94

# 从非致病性大肠杆菌到志贺氏菌的进化




*Clin Microbiol Rev*, 2008, 21(1): 134–156


# 志贺氏菌毒力调控因素




▶ 用比较蛋白质组学发现了潜在的抗毒力基因 *argT*  
 (不同温度条件下——30°C和37°C)



**ArgT:** 赖氨酸、精氨酸等碱性氨基酸转运蛋白




# 抗毒力基因



将是今后病原菌研究中的一大热点。


## 抗毒力基因(anti-virulence genes):

- 在其进化的无毒祖先菌株中稳定存在和表达，而在病原菌中缺失或不表达；
- 在病原菌中强制表达该基因，会降低病原菌的毒力。






➤发现了**ArgT** 的降解发生在周间质中





➤ 发现了降解ArgT的蛋白酶HtrA







# ➤ ArgT在志贺氏菌和大肠杆菌中存在差异



# 验证了 ArgT 的抗毒力功能




➤ 抗毒力因子**ArgT**的降解调控示意图




细菌微进化 (SNP) 与毒力的关系


➤ 发现ArgT的丰度与HtrA的修饰有关




## ➤ HtrA不同表达模式全菌蛋白2D结果 (pH6-11)



## ➤ HtrA不同表达模式全菌蛋白2D结果 (pH4-7)




## ➤ 蛋白差异点质谱分析结果



**OsmY**是一种周间质蛋白，**Dps**具有与铁离子结合和抗氧化损伤功能，这种变化表明**HtrA**与应激系统有关连。

## ➤ 进一步确认翻译后修饰存在的可能性



排除酶活位点存在修饰的可能性

# ➤ 高分辨率质谱分析(LC-MS/MS)

```

1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
  
```

```

1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
251 NTAIlAPDGG NIGIGFAIPs NMVKNLTSQm VEYgQVKRGe LGIMGTBLNS
301 ELAKAMKVDA QRGAfVSOVL PNSSAAKAGI KAGDVITSLN GKPISSFAAL
  
```

```


1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
  
```

```

1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
251 NTAIlAPDGG NIGIGFAIPs NMVKNLTSQm VEYgQVKRGe LGIMGTBLNS
301 ELAKAMKVDA QRGAfVSOVL PNSSAAKAGI KAGDVITSLN GKPISSFAAL
351 RAQVGTMpVg SKLTLGLLRD GKQVNVNLEL QQSSQNVdS SSIFNGIEGA
401 EMSNKGKdQg VVVNVKTGT PAAQIGLKKg DVIIGANQQA VKNIABLRKV
451 LDSKPSVLAL NIQRGDSTIY LLMQ
  
```

Trypsin

Glu-C



Chymotrypsin

TrypChymo

```

1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
  
```

```

1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
251 NTAIlAPDGG NIGIGFAIPs NMVKNLTSQm VEYgQVKRGe LGIMGTBLNS
301 ELAKAMKVDA QRGAfVSOVL PNSSAAKAGI KAGDVITSLN GKPISSFAAL
  
```


```

1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
  
```

```


1 MKKNTLALSA LALSLGLALS PLSATAAETS SATTAAQMPs LAPMLEKVMP
51 SVVsinVEGS TTVNTPRMPr NFQQFFGDdS PFCQEGSPFQ SSPFCQGGQg
101 GNGGGQQQKf MALGSGVIID ADKGYVVTNN HVVDNATVIK VQLSDGRKfD
151 AKMVGKdPRs DIALIQIqNP KKLTAIKMAD SDALRVGDYt VAIGNPFGLg
201 ETVTSGIVsA LGRSGLNAEN YENFIQTDAa INRGNSGGAL VNLNGELIGI
251 NTAIlAPDGG NIGIGFAIPs NMVKNLTSQm VEYgQVKRGe LGIMGTBLNS
301 ELAKAMKVDA QRGAfVSOVL PNSSAAKAGI KAGDVITSLN GKPISSFAAL
351 RAQVGTMpVg SKLTLGLLRD GKQVNVNLEL QQSSQNVdS SSIFNGIEGA
401 EMSNKGKdQg VVVNVKTGT PAAQIGLKKg DVIIGANQQA VKNIABLRKV
451 LDSKPSVLAL NIQRGDSTIY LLMQ
  
```

## ➤ LC-MS/MS结果小结




## ➤ 利用点突变寻找修饰位点

**C Q E G S P F**




排除87位S存在修饰的可能性

# 志贺氏菌复合物的分离与鉴定




**Blue-Native/SDS-PAGE双向电泳**


# 志贺氏菌复合物的分离与鉴定



A. 6%-11% 梯度BN-PAGE及12.5% SDS-PAGE




B. 10%-16% 梯度BN-PAGE及12.5% SDS-PAGE



PhoN1-毒力大质粒编码的未知功能蛋白  
 UshA-双功能酶  
 YghZ-假想还原酶


# 大肠杆菌和志贺氏菌SOD复合物的比较




## SodB

E. coli  $\xrightarrow{\text{文献报道}}$  43KD同源二聚体


2457T  $\xrightarrow{\text{2-D电泳结果}}$  66KD同源多聚体




# 志贺氏菌毒力因子复合物的分析



# 不同温度下志贺氏菌复合物差异的比较



# 差异复合物的鉴定与验证



四个蛋白复合物:

PyrB/PyrI ATCase

(天冬氨酸转氨甲酰酶复合物)

MglB MglABC


(半乳糖ABC转运蛋白复合物)

GlmS GFAT


L-谷氨酰胺:D-果糖-6-磷酸氨基转移酶复合物

GcvP Glycine decarboxylase


(甘氨酸裂解系统复合物)




# 差异表达复合物参与LPS的合成




# 温度影响LPS的合成





2457T 37°C



2457T 30°C



# 志贺氏菌T3SS与LPS间的关系



# 致 谢

---

□ 科技部

□ 国家自然科学基金委员会

□ 总后卫生部

□ 课题组成员

刘先凯 朱 力  
冯尔玲

□ 研究生

赵 格 曹晓玉  
牛 畅 商 娜  
杨 晶

# 谢谢！


联系方式： 军事医学科学院八所 王恒樑

**13683605741, 010-66948836**

**wanghl@nic.bmi.ac.cn**

# 抗毒力基因的研究策略


比较基因组学方法（文献）



已发现的抗毒力基因及其作用机制：



比较蛋白质组学方法（本研究）



非毒力状态

毒力状态



将发现一类新的抗毒力基因：



获得致病菌适应性进化的新证据和新途径。